

Leukemia & Lymphoma >
Volume 49, 2008 - Issue 11574 | 51 | 6
Views | CrossRef citations to date | Altmetric

Original Articles: Clinical

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

Sucha Nand , John Godwin, Scott Smith, Kevin Barton, Laura Michaelis, Serhan Alkan, ... show all

Pages 2141-2147 | Received 16 Jun 2008, Accepted 27 Aug 2008, Published online: 01 Jul 2009

 Cite this article  <https://doi.org/10.1080/10428190802451254>

Sample our
Medicine, Dentistry, Nursing
& Allied Health Journals
>> **Sign in here** to start your access
to the latest two volumes for 14 days

 Full Article  Figures & data  References  Citations  Metrics Reprints & Permissions[Read this article](#)

Abstract

Elderly patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes were treated with a standard of care regimen consisting of hydroxyurea, azacitidine and gemtuzumab. The treatment was well tolerated and resulted in a significant increase in the blood cell count before the start of the second cycle.

About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings

and GO 3 mg/m² on day 8. Patients who achieved complete remission (CR) received a consolidation course. The median age of patients was 76 years. Eleven patients (55%) were treated in the outpatient setting. Fourteen (70%) achieved a CR, three of which were incomplete (CRi). The median duration of remission was 8 months and median survival was 10 months. Performance status of 0–1 was associated with high complete response rate. Overall toxicity was acceptable with only one (5%) early death due to disease progression. The combination of HU, azacitidine and GO appears to be a safe and effective regimen in the treatment of AML and high risk MDS in the elderly. These results need to be confirmed in a larger cohort of patients.

Keywords: Acute myeloid leukemia azacitidine gemtuzumab ozogamicin

Related research

People also read

Recommended articles

Cited by
51

A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplas... >

Sarit Assouline et al.

Leukemia & Lymphoma

Published online: 14 Dec 2022

About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our [Privacy Policy](#).

 Accept All

Essential Only

Settings



Information for

Authors
R&D professionals
Editors
Librarians
Societies

Opportunities

Reprints and e-prints
Advertising solutions
Accelerated publication
Corporate access solutions

Open access


Overview
Open journals
Open Select
Dove Medical Press
F1000Research

Help and information

Help and contact
Newsroom
All journals
Books

Keep up to date


Register to receive personalised research and resources by email

 Sign me up



Copyright © 2024 Informa UK Limited Privacy policy Cookies Terms & conditions

Accessibility



About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click “Settings”. For further information about the data we collect from you, please see our [Privacy Policy](#).

 Accept All

Essential Only

Settings